Roche continues to drag its feet on access to Tamiflu dataBMJ 2013; 346 doi: https://doi.org/10.1136/bmj.f3001 (Published 15 May 2013) Cite this as: BMJ 2013;346:f3001
- Peter C Gøtzsche, professor1
- 1Nordic Cochrane Centre, Rigshospitalet, Denmark
Four years after it was first promised (but not fulfilled), Roche is again offering Cochrane researchers access to its trial reports on Tamiflu. But Roche is offering less than full transparency: “In line with European Union law, each CSR [clinical study report] will be edited by Roche to ensure patient confidentiality and to protect legitimate commercial interests.”1 Furthermore, Roche says …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial